BioTelemetry (BEAT) Tops Q2 EPS by 15c

BioTelemetry (NASDAQ: BEAT) reported Q2 EPS of $0.46, $0.15 better than the analyst estimate of $0.31. Revenue for the quarter came in at $101.4 million versus the consensus estimate of $95.86 million.

GUIDANCE:

BioTelemetry sees Q3 2018 revenue of $392-395 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
• Morgan Stanley upgrades CDW on stronger AI-driven server demand